This document discusses potential synergies between the healthcare/hospital sector and businesses. It outlines how university hospitals can drive innovation through biomedical research, medical training, and healthcare delivery. The document advocates for integrating innovation into regular hospital activities and establishing support structures to help extract innovative ideas from clinical knowledge. It also describes the need to partner with strategic partners and private enterprises to validate ideas, develop prototypes, obtain intellectual property rights, and commercialize innovations.

1. SINERGIAS ENTRE EL SECTOR SANITARIO
(HOSPITALARIO)Y EL EMPRESARIAL
JOSEV. CASTELL PHD, MD
DIRECTOR

2. UNIVERSITY HOSPITALS :
BIOMEDICAL
RESEARCH
MEDICALTRAINING
HEALTHCARE

3. HIGHLY QUALIFIED PERSONNEL +
ADVANCED TECHNOLOGIES

4. GREAT INNOVATIVE POTENTIAL …
4

5. Potential ideas / value run out…
Clinical care

6. Recovering “energy” : a co-generation model?

8. INNOVATION IN UNIVERSITY HOSPITALS
BIOMEDICAL
RESEARCH
INNOVATION
MEDICAL
TRAINING
HEALTHCARE

9. INTEGRATING INNOVATION IN HOSPITAL ACTIVITY
 Innovation is NOT a first priority in hospitals
 Innovation should be integrated and be part of
the current activity of health professionals
 Support structures should be implemented in
order to “extract” potential innovations out of
clinical knowledge

13. Ideas / biomedical research
Strategic Validation Process
Prototypes – Proof of concept
Integration in healthcare practice
Successful
INNOVATION
is complex
Intellectual Property Rights IPRs
ClinicalValidation
Commercialization
Feedback and improvement

14. Idea / biomedical research
Strategic Validation Process
Prototype – Proof of concept
Diffusion and adoption in Healthcare
Intellectual Property Rights IPRs
ClinicalValidation
Commercialization
Feedback and improvement
Successful
INNOVATION
is complex

15. The clinical proof of
concept/validation
Other partners needed??
working with strategic partners

16. Idea Licencing-SME Valorization Commercialization
Large investments
not always affordable

20. Ideas Licencing-SME Valorization Commercialization
“ ”

21.  Linking agents of the Science-
technology-Enterprise System, to
accelerate the process of
valorization, transferability and
the way to market in the field of
biomedical research
 Hosting biomedical enterprises
Basic
Research
Clinical
Reseach
Valorization
and
Innovation
Transfer to
product
developers

22. Biopole: 15.400 m2
Medical Faculty &
Management area:
13.500m2
Medical Care area: 166.400 m2
22

23. SME/ IIS La Fe Partnership

24. IDEA /
PRODUCT

25. CRUnit
(biomedicalcontract
researchUnit)

26. PLATFORMS
The IIS La Fe offers scientific and technological services with more than 10,000 m2 of
clinical and research laboratories
CRUnit
Omic Platform
Genomics
Cytomics
Analitycal Unit
Biomedical
Research Support
Pre-Clinical
Toxicity Platform
Cell Culture
Models
Animal Models
Clinical Genetic
Platform
Pharmacogenetics
Cytogenetic
Analysis
Genetic Anlysis

27. PRE-CLINICAL
TOXICITY
PLATFORM
Cell Culture Models
cellculture_toxicity@iislafe.es
Genotoxicity Hepatotoxicity Phototoxicity
Animal Models
animalmodel_toxicity@iislafe.es
Drug and Food
Toxicity
Ecotoxicity
Coordinates preclinical or environmental studies in different levels of complexity from in
vitro cellular models to animal models for a wide variety of toxicological studies.
The know-how and validated systems generated indoors are of great value in order to provide with
high quality experimental designs and accurate and reliable results promoting fast decision-making

28. RESEARCH OMIC
PLATFORM
Genomics
genomics@iislafe.es
Arrays
arrays_service@iislafe.es
Genotiping and
Sequencing Cytogenetics
Cytomics
cytomics@iislafe.es
Analytical Unit
analytical_unit@iislafe.es
Metabolics/MS
Proteomics
It is a powerful platform for the analysis, validation
and interpretation of massive data sets
Merges a set of high-tech disciplines such as Genomics, Cytomics, Metabolomics
and Proteomics.

29. Offers a customised global GLP
service:
- including analytical services,
- consultancy, as well as
- the development of analytical
methods
Request
study
Tailored
design
Resultsin
compliance
with regulation
Quickproblem solving
Fast-decisionmaking
CUSTOMERNEEDS

30. Enzymatic
activities
Biomarkers
Metabolomic
profile
Secondary
metabolism
compounds
Signal
transduction
molecules
Target molecules
from
biotransformation
processes
Expertise and professionals at your
disposal for a wide variety of
analytical determinations in
compliance with GLP principles:

31. IDEA /
PRODUCT
Stock Options or Shares,
Capital return
Costs paid in
valorization Procces

32. SHARING FUTURE VALUE

33. www.iislafe.es